A Phase 3 study of KHK4827 in patients with systemic sclerosis
A Phase 3, placebo-controlled, double-blind comparative study of KHK4827 with an open-label extension period in subjects with systemic sclerosis who have moderate to severe skin thickening A Phase 3, placebo-controlled, double-blind comparative study of KHK4827 with an open-label extensio ...
Systemic sclerosis
Intervention name : KHK4827 INN of the intervention : Brodalumab Dosage And administration of the intervention : 210 mg Q2W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : 210 mg Q2W, SC Intervention name : KHK4827 INN of the intervention : Brodalumab Dosage And administration of the inte ...
A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis
A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis
systemic sclerosis
Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : SC, 210 mg Q2W Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the inte ...